Korean Botox Brands: A Comparison Guide

Korean Botox brands now represent a broad range of botulinum toxin type A products that differ in manufacturing process, liquid formulations, protein load, vial sizing, clinical evidence, and regulatory status. For medical professionals comparing the best Korean Botox brands, country of manufacture is only one consideration; each product has its own formulation, evidence base, and regulatory profile.

This article explores leading Korean botulinum toxin products, how they differ from one another and from Western brands, and what practitioners should consider when comparing formulations.

At Doctor Medica, we provide information on Korean Botox for licensed medical professionals evaluating different injectable options. Looking to buy Korean botox online? Get in touch with our customer service representatives at Doctor Medica for further guidance.

Key Takeaways

• Korean botulinum toxin products share the same general neuromuscular mechanism, but can differ in formulation, purification processes, protein composition, vial size, and regulatory status.
• LETYBO® and NABOTA®/JEUVEAU® are among the Korean brands with substantial international clinical data and U.S. regulatory recognition for specific aesthetic indications.
• There is no single best Korean Botox brand for every clinic. Selection should weigh the approved indication, supporting evidence, formulation, dosing system, patient profile, and local regulations.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices in the market. If you’re looking to buy Korean Botox for your practice, contact Doctor Medica today.

How Should Korean Botox Brands Be Compared?

The term Korean Botox brands refers to a diverse range of injectable botulinum toxin type A products developed by South Korean pharmaceutical manufacturers. Although they are often discussed collectively, differences between individual Korean botulinum toxin products can matter clinically.

Major names include LETYBO® and BOTULAX® from Hugel, NABOTA® from Daewoong Pharmaceutical, and products from Medytox such as INNOTOX® and MEDITOXIN®. The category spans both traditional lyophilized powders and ready-to-use liquid formulations.

Regulatory status is one of the clearest points of divergence. LETYBO®, or letibotulinumtoxinA-wlbg, received U.S. approval in 2024 for the temporary improvement of moderate to severe glabellar lines in adults. JEUVEAU®, the U.S. brand of prabotulinumtoxinA manufactured by Daewoong, received U.S. approval in 2019 for the same general aesthetic indication. INNOTOX®, by contrast, is approved by Korea’s Ministry of Food and Drug Safety (MFDS) but does not currently hold FDA approval in the United States.

Other Korean Botox products may be approved in South Korea or other jurisdictions without equivalent U.S. approval, so practitioners should verify regulatory status for each product and market.

Which Korean Botox Brands Have Expanded Internationally?

Several Korean botulinum toxin products have expanded well beyond the domestic South Korean market. LETYBO® and NABOTA® are two Korean-developed products with an international market presence and published clinical data.

LETYBO®

LETYBO® contains letibotulinumtoxinA and is manufactured by Hugel. Its U.S. prescribing information identifies it as an acetylcholine-release inhibitor and neuromuscular-blocking agent for moderate to severe glabellar lines in adults. U.S. presentations include 50-unit and 100-unit single-dose vials.[5]

In a Phase III study involving 355 participants, 20 units of letibotulinumtoxinA produced significantly greater improvement in glabellar-line severity than placebo. The median onset was three days, and the mean time to first retreatment was approximately 127 days.[2]

NABOTA® and JEUVEAU®

NABOTA® is manufactured by Daewoong Pharmaceutical. The same active toxin, prabotulinumtoxinA, is marketed in the United States as JEUVEAU®.

Daewoong lists NABOTA® internationally in 50-, 100-, and 200-unit vial presentations, although available sizes and approvals vary between markets. JEUVEAU® in the United States is supplied as a 100-unit single-dose vial.[4]

The EVB-003 study, a 540-patient Phase III noninferiority trial conducted across Europe and Canada, compared 20 units of prabotulinumtoxinA with 20 units of onabotulinumtoxinA for moderate to severe glabellar lines. Responder rates at Day 30 were 87.2% and 82.8%, respectively, and prabotulinumtoxinA met the trial’s noninferiority criterion.[3]

NABOTA® and JEUVEAU® should not be assumed to be interchangeable solely because they are associated with the same active toxin, as presentations, approvals, and labeling can differ by market.

What Differences Matter Between Korean Botox Brands?

Botulinum toxin is a biologic. Each manufacturer uses its own bacterial strains, fermentation methods, purification processes, potency assays, excipients, and finishing techniques, and the manufacturing process is one of the clearest places where Korean toxin products diverge.

Laboratory analysis of several Asian products has identified differences in measured neurotoxin protein content among products such as BOTULAX®, MEDITOXIN®, NABOTA®, and XEOMIN®. These findings show that products grouped under the same toxin serotype are not necessarily identical at the formulation level.[1]

Protein Load and Load Diffusion

The protein load of a botulinum toxin preparation refers broadly to the protein material associated with its formulation. Some products contain the active 150-kDa neurotoxin together with accessory or complexing proteins, while others are manufactured without those complexing proteins.

Protein composition may matter when discussing immunogenicity, but it should not automatically predict clinical potency, effectiveness, or load diffusion. Research suggests that protein complexation itself is not the primary determinant of how the active toxin diffuses after injection.[1] For practitioners interpreting marketing material, that caveat matters because formulation claims are sometimes extended to performance claims the underlying data do not support.

Liquid and Lyophilized Formulations

Dosage form is another practical difference between products. Most established Korean toxins are supplied as dried powders that require reconstitution before administration. INNOTOX®, by contrast, is supplied as a ready-to-use liquid formulation.

For a clinic, the distinction between lyophilized and liquid formulations may affect preparation time and workflow. It does not, by itself, establish clinical superiority of one product over another.

Comparing Vial Sizes and Units

A 100-unit vial is common, though available presentations vary by brand and by market:

• U.S. LETYBO®: 50-unit and 100-unit vial
• U.S. JEUVEAU®: 100-unit vial
• NABOTA® internationally: 50-, 100-, and 200-unit vial options

Vial size mainly affects inventory and treatment planning. It does not indicate greater potency, and it does not mean units can be converted directly between brands. Botulinum toxin units are product-specific, so dosing should follow the individual product information, approved indication, and treatment plan. For clinics researching where to buy Korean Botox brands online, supplier credentials, product documentation, storage requirements, and handling practices are additional considerations. Shipping conditions matter for this product class, since temperature excursions during transit can compromise stability, and cold-chain verification should be confirmed with the supplying distributor.

How Do Korean Products Compare With U.S. and Other Western Brands?

The difference between Korean and American botulinum toxin products comes down more to formulation, clinical evidence, and regulatory history than to country of origin.

Established American and Western products such as BOTOX® Cosmetic have a longer clinical history, while Korean-developed products have built a growing body of comparative data. The EVB-003 noninferiority trial referenced above is one of the better-known examples supporting individual Korean toxins against established Western comparators.[3]

These findings support individual products rather than Korean toxins as a single category. Product-level comparison is more informative than framing by country of origin.

What Clinical Factors Matter Beyond the Brand Name?

Brand and formulation are only part of the comparison. Practitioners should also consider how botulinum toxin acts at the neuromuscular junction, which treatment areas are supported by product-specific labeling, what clinical studies suggest about duration, and the safety information associated with each formulation.

How Does Botulinum Toxin Work?

Botulinum toxin type A acts at the neuromuscular junction by binding to motor nerve terminals and interfering with acetylcholine release through cleavage of SNAP-25. By reducing acetylcholine release, the toxin temporarily decreases signaling to the targeted muscle and lowers local muscle activity. This mechanism underlies its classification as a neuromuscular-blocking agent, or muscle relaxant.[4]

Which Treatment Areas Are Commonly Addressed?

The appropriate treatment area depends on the product’s approved indication, labeling, and clinical context. For glabellar lines, treatment typically targets the corrugator and procerus muscles.

Botulinum toxin may also be used in other aesthetic areas, including forehead lines, lateral canthal lines, and selected facial-contouring applications. Because approved indications vary by product and jurisdiction, practitioners should refer to the relevant product labeling when evaluating a particular use.

What Does Research Suggest About Duration?

Duration should be evaluated at the individual product level rather than assumed from a product’s country of manufacture. Dose, treatment area, muscle activity, injection technique, and individual response can all influence how long visible effects persist.

For LETYBO®, a Phase III study reported a mean time to first retreatment of approximately 127 days following glabellar-line treatment.[2] Available evidence does not establish that Korean botulinum toxin products, as a category, consistently produce longer-lasting results than Western alternatives.[2]

Product-specific clinical data are therefore more informative than broad assumptions about Korean Botox results based solely on origin.

What Safety Information Should Practitioners Review?

Safety profiles vary by product, dose, treatment area, and patient factors. For LETYBO®, headache is listed among the most common adverse reactions associated with glabellar-line treatment, while JEUVEAU® carries its own product-specific safety information and warnings.[4][5]

Botulinum toxin injections may also be associated with temporary injection-site reactions or unintended weakness in nearby muscles. Product labeling warns that, in rare cases, toxin effects may spread beyond the injection area and lead to symptoms such as muscle weakness, difficulty swallowing, speech changes, or breathing problems.[4][5]

Careful patient selection, accurate dosing, knowledge of facial anatomy, and adherence to the individual product label remain important when managing treatment-related risks.

Why Have Korean Botox Brands Gained Global Visibility?

Korean botulinum toxin products have gained visibility in global markets because of expanding clinical evidence, varied formulations, international approvals, and competitive pricing. Price can influence product comparisons, but it should be considered alongside regulatory status, clinical evidence, formulation, and supplier controls.

Practitioners sourcing Korean Botox brands wholesale should confirm cold-chain compliance, LOT number traceability, supplier credentials, and sealed-packaging documentation before accepting delivery. Requirements for purchasing Korean botox brands online also differ by jurisdiction, and licensed professionals should verify what their regional regulations permit before placing orders.

Interest in Korean aesthetics also extends beyond injectables. Korean botox balm, for example, reflects a separate topical skincare trend that practitioners occasionally field questions about.

LETYBO® and NABOTA®/JEUVEAU® should ultimately be evaluated according to their individual clinical evidence, labeling, formulation, and regulatory status.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Citations

[1] Frevert, Jürgen et al. “Comparison of botulinum neurotoxin type A formulations in Asia.” Clinical, cosmetic and investigational dermatology vol. 11 327-331. 5 Jul. 2018, doi:10.2147/CCID.S160723

[2] Mueller, Daniel S et al. “Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study.” Aesthetic surgery journal vol. 42,6 (2022): 677-688. doi:10.1093/asj/sjac019

[3] Rzany, Berthold-Josef et al. “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.” Aesthetic surgery journal vol. 40,4 (2020): 413-429. doi:10.1093/asj/sjz110

[4] Evolus, Inc. “JEUVEAU® (PrabotulinumtoxinA-xvfs) for Injection, for Intramuscular Use: Full Prescribing Information.” DailyMed, revised Apr. 2023, dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=17a914c1-e54b-4b50-965d-b0fd9111bba4.

[5] Hugel, Inc. “LETYBO® (LetibotulinumtoxinA-wlbg) for Injection, for Intramuscular Use: Full Prescribing Information.” DailyMed, revised Nov. 2024, dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=910e5d0e-4d0b-4de8-8e2d-97879a044181.